Expertise in
13
conditions

Dr. Daniel F. Soteres

Allergy and Immunology
Asthma And Allergy Associates PC
2709 N Tejon St, 
Colorado Springs, CO 
Accepting New Patients
Referral may be required
Before you request
Expertise in
13
conditions
Asthma And Allergy Associates PC
2709 N Tejon St, 
Colorado Springs, CO 

Overview

Daniel Soteres is an Allergy and Immunologist practicing medicine in Colorado Springs, Colorado.

Dr. Soteres is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Angioedema, Hereditary Angioedema, Hives, and Sinusitis.

Dr. Soteres is board certified in American Board Of Allergy And Immunology. He is actively involved in clinical research, co-authoring 30 peer reviewed articles and participating in 15 clinical trials. Dr. Soteres is currently accepting new patients.

Specialties

Allergy and Immunology

Licenses

Allergy & Immunology in CO

Board Certifications

American Board Of Allergy And Immunology

Fellowships

Tulane University Hops and Clinics

Hospital Affiliations

Uch-Memorial Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Freedom Life
  • INSURANCE PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 20 Less Insurance Carriers -

Locations

Asthma And Allergy Associates Pc
2709 N Tejon St, Colorado Springs, CO 80907
Other Locations
Asthma And Allergy Associates Pc
595 Chapel Hills Dr Ste 240, Colorado Springs, CO 80920

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: November 05, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Longitudinal Observational Study of Patients With Chronic Disease
A Longitudinal Observational Study of Patients With Chronic Disease
Enrollment Status: Terminated
Publish Date: April 03, 2025
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: June 17, 2024
Intervention Type: Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Drug: Lanadelumab
Study Phase: Phase 3
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
Enrollment Status: Completed
Publish Date: March 30, 2023
View 9 Less Clinical Trials

30 Total Publications

Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis.
Real-world quality of life in patients with hereditary angioedema receiving lanadelumab or other long-term prophylaxis.
Journal: Allergy and asthma proceedings
Published: March 17, 2026
Similar Doctors
Expertise in
12
conditions
Dr. James W. Fulton
Allergy and Immunology
Expertise in
12
conditions
Dr. James W. Fulton
Allergy and Immunology
Referral may be required
Before you request

Asthma And Allergy Associates PC

2709 N Tejon St, 
Colorado Springs, CO 
 (0.1 miles away)
719-473-0872
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Fulton is an Allergy and Immunologist practicing medicine in Colorado Springs, Colorado. Dr. Fulton is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Allergic Conjunctivitis, Conjunctivitis (Pink Eye), Chronic Spontaneous Urticaria (CSU), and Vibratory Urticaria. Dr. Fulton is board certified in Allergy & Immunology-American Board Of Allergy & Immunology (ABAI) and American Board Of Internal Medicine. Dr. Fulton is currently accepting new patients.

Expertise in
18
conditions
Dr. Flavia C. Hoyte
Allergy and Immunology
Expertise in
18
conditions
Dr. Flavia C. Hoyte
Allergy and Immunology
Referral may be required

National Jewish Health

1400 Jackson Street, Allergy And Immunology Dept, 
Denver, CO 
 (60.3 miles away)
303-388-4461
Languages Spoken:
English
See accepted insurances
Offers Telehealth

National Jewish Health. Dr. Hoyte is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Asthma, Simple Pulmonary Eosinophilia, Chronic Eosinophilic Pneumonia, and Eosinophilic Pneumonia. Dr. Hoyte is board certified in American Board Of Pediatrics and American Board Of Allergy And Immunology .

Expertise in
6
conditions
Dr. Matthew J. Greenhawt
Allergy and Immunology
Expertise in
6
conditions
Dr. Matthew J. Greenhawt
Allergy and Immunology
Referral may be required

Children's Hospital Colorado

13123 E 16th Ave, 
Aurora, CO 
 (60.2 miles away)
720-777-2575
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Greenhawt is an Allergy and Immunologist practicing medicine in Aurora, Colorado. Dr. Greenhawt is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Anaphylaxis, Food Allergy, Asthma, and Eosinophilic Esophagitis. Dr. Greenhawt is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel F. Soteres

How do I make an appointment with Dr. Daniel F. Soteres?

You can book an appointment with Dr. Daniel F. Soteres by calling their office at 719-473-0872. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel F. Soteres a top-rated expert for Angioedema?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel F. Soteres is classified as an Elite expert for Angioedema, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel F. Soteres specialize in?

While Dr. Daniel F. Soteres is a Allergy and Immunology, they have specific expertise in Angioedema, Hereditary Angioedema, and Hives. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Allergy and Immunology.

Does Dr. Daniel F. Soteres participate in research or clinical trials?

Yes. Dr. Daniel F. Soteres has published 30 articles and abstracts on conditions like Angioedema. You can view a list of Dr. Daniel F. Soteres's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel F. Soteres accept my insurance?

Dr. Daniel F. Soteres accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 719-473-0872 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Soteres's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile